| Study Name | Description | Trial Category | Trial SubCategory |
|---|---|---|---|
| Samsung Wrist Worn Device | The objective of this study is to collect physiological signals in Atrial Fibrillation patients to develop and validate the Irregular Heart Rhythm Notification feature on Samsung device. The study subject will have a documented history of Atrial Fibrillation. | Heart & Vascular | Atrial Fibrillation |
| CanGaroo | The objective of this study is to explore the subject clinical profiles, procedural details and post-implant outcomes of patients who receive either the CanGaroo ECM Envelope or no envelope at the time of initial implantation. | Heart & Vascular | Atrial Fibrillation |
| Grifols Covid | The objective of this study is to evaluate the safety and efficacy of liquid alpha-proteinase inhibitor versus placebo in subjects with Covid-19. Patient must be admitted to hospital with a confirmed positive COVID result. | Pulmonary | Covid |
| HSY244 | The objective for this study is to evaluate the efficacy, pharmacokinetics, safety and tolerability of HSY244 to restore sinus rhythm in patients with Atrial Fibrillation (AF). The study subjects have current ongoing episodes of AF for more than 6 hours and less than 30 days. | Heart & Vascular | Atrial Fibrillation |
| Leadless II | The primary objectives for this study are to confirm the safety and effectiveness of the Abbott Aveir LP System in subject population indicated for a VVI® pacemaker. | Heart & Vascular | Cardiac Arrhythmia |
| A011202 | A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy https://clinicaltrials.gov/ct2/show/NCT03797326?term=NCT03797326&draw=2&rank=1 | Cancer | Breast |
| A011801 | The CompassHER2 Trials (Comprehensive Use of Pathologic Response Assessment to Optimize Therapy in HER2-Positive Breast Cancer) CompassHER2 Residual Disease (RD), a Double-Blinded, Phase III Randomized Trial of T-DM1 Compared With T-DM1 and Tucatinib https://clinicaltrials.gov/ct2/show/NCT04457596?term=NCT04457596&draw=2&rank=1 | Cancer | Breast |
| A221805 | Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase II to Phase III Study https://clinicaltrials.gov/ct2/show/NCT04137107?term=NCT04137107&draw=2&rank=1 | Cancer | Gastrointestinal |
| ACCRU-BR-1801 | A Phase II Trial of Abemaciclib and T-DM1 in Women and Men with HER2 positive Advanced or Metastatic Breast Cancer Who Progressed on Treatment with a Taxane, Trastuzumab and Pertuzumab https://clinicaltrials.gov/ct2/show/NCT04351230?term=NCT04351230&draw=2&rank=1 | Cancer | Breast |
| EA2176 | A Randomized Phase III Study of Immune Checkpoint Inhibition with Chemotherapy in Treatment-Naïve Metastatic Anal Cancer Patients https://clinicaltrials.gov/ct2/show/NCT04444921?term=NCT04444921&draw=2&rank=1 | Cancer | Gastrointestinal |
| EA2187 | A Phase 2 Study of Penvonedistat in Combination with Carboplatin and Paclitaxel in Advanced Intrahepatic Cholangiocarcinoma https://clinicaltrials.gov/ct2/show/NCT04175912?term=NCT04175912&draw=2&rank=1 | Cancer | Gastrointestinal |
| NRG-GY009 | Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients with Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum https://clinicaltrials.gov/ct2/show/NCT03797326?term=NCT03797326&draw=2&rank=1 | Cancer | Other |
| S1613 | A randomized Phase II study of Trastuzumab and Pertuzumab (TP) compared to Cetuximab and Irinotecan (Cetiri) in advanced/metastatic colorectal cancer (MCRC) with Her-2 amplification https://clinicaltrials.gov/ct2/show/NCT03365882?term=S1613&draw=2&rank=1 | Cancer | Other |
| S1925 | S1925 Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab Versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study https://clinicaltrials.gov/ct2/show/NCT04269902?term=NCT04269902&draw=2&rank=1 | Cancer | Hematology |
| A DUE | Clinical Study to Compare the Efficacy and Safety of Macitentan and Tadalafil Monotherapies With the Corresponding Fixed-dose Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH) | Heart & Vascular | Pulmonary Hypertension |
| A021703 | Randomized Double-Blind Phase III Trial of Vitamin D3 Supplementation in Patients with Previously Untreated Metastatic Colorectal Cancer (SOLARIS) | Cancer | Gastrointestinal |
| A031501 | Phase III Randomized Adjuvant Study of MK-3475 (Pembrolizumab) in Muscle Invasive and Locally Advanced Urothelial Carcinoma (AMBASSADOR) Versus Observation | Cancer | Bladder/Urothelial |
| A031803 | Phase II Trial of Intravesical Gemcitabine and MK-3475 (pembrolizumab) in the Treatment of Patients with BCG-Unresponseve Non-Muscle Invasive Bladder Cancer | Cancer | Bladder |
| A041702 | Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (= 70 Years of Age) | Cancer | Hematology |
| A061202 | A Phase I/II Study of Pomalidomide, Dexamethasone and Ixazomib VS. Pomalidomide and Dexamethasone for Patients with Multiple Myeloma Relapsing on Lenalidomide as Part of First Line Therapy | Cancer | Multiple Myeloma |
| AALL08B1 | Classification of Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) | Childhood Cancers | Leukemia |
| AALL0932 | Treatment of Patients with Newly Diagnosed Standard Risk B-Precursor Acute Lymphoblastic Leukemia (ALL) | Childhood Cancers | Leukemia |
| AALL1231 | A Phase lll Randomized Trial Investigating Bortezomib (NSC#681239; IND# 58443) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy) | Childhood Cancers | Leukemia |
| AALL1521 | A Phase 2 study of the JAK1/JAK2 Inhibitor Ruxolitinib with Chemotherapy in Children with De Novo High-Risk CRLF2 Rearranged and/ or JAK Pathway-Mutant Acute Lymphoblastic Leukemia | Childhood Cancers | Leukemia |
| Acoustic Diagnosis of Gastroesophageal Reflux Disease | Baby/Child | Reflux Disease | |
| AIM Power | The goal of this real-world, multi-center, randomized, outpatient study is to assess the effectiveness of the Biofourmis cloud based BiovitalsHFTM Clinical Decision Support Platform to recommend optimal titration of Guideline-Directed Medical Therapy (GDMT) for heart failure with reduced ejection fraction (HFrEF) subjects. | Heart & Vascular | Heart Failure |
| ANBL1232 | Utilizing Response-and Biology-Based Risk Factors to Guide Therapy in Patients with Non-High Risk Neuroblastoma | Childhood Cancers | Blastoma |
| ANT-006 / Azalea | Patient must be 55 years old or older to be eligible for the study. | Heart & Vascular | Atrial Fibrillation |
| APEC14B1 EveryChild | A Registry, Eligibility Screening, Biology and Outcome Study | Childhood Cancers | Registry |
| Artesia | Apixaban for the Reduction of Thrombo-Embolism in Patients with Device-Detected Sub-Clinical Atrial Fibrillation | Heart & Vascular | Atrial Fibrillation |
Unsupported Browser! This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.